Open AccessCost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]
Author(s) -
María Mareque,
Pau Montesinos,
Patricia Font,
José María Guinea de Castro,
Adolfo de la Fuente,
Javier Soto,
Itziar Oyagüez,
James Brockbank,
Tamara Iglesias,
Julia Llinares,
Jorge Sierra
Publication year - 2021
Publication title -
clinicoeconomics and outcomes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.591
H-Index - 27
ISSN - 1178-6981
DOI - 10.2147/ceor.s328284
Subject(s) - medicine , gemtuzumab ozogamicin , myeloid leukaemia , first line , pediatrics , genetics , cd33 , biology , stem cell , cd34
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom